Fracture
1
Adil et al. [72]
UN
UN
N
Random
OR
1.33
1.09–1.64
0.006
UN
UN
⨁⨁◯◯
Low
2
Arnott et al. [28]
NR
RR
Total: 1.07
T2DM: 1.06
CKD: 1.03
HF: 1.06
0.99–1.15
0.97–1.15
0.87–1.22
0.89–1.27
0.089
0.191
0.714
0.5
0
2.1
0
0
0.834
0.551
0.441
0.956
⨁⨁⨁◯
Moderate
3
Arnott et al. [29]
Empagliflozi (10, 25), Canagliflozi (100, 300), Dapagliflozin (10)
mean 139
Y
Fixed
RR
Overall:1.08
0.98, 1.18
0.127
20.3
0.288
⨁⨁⨁⨁
High
4
Augusto et al. [30]
(2021)
Dapagliflozin (2.5, 5, 10) Empagliflozin (10, 25), Canagliflozin (100, 200, 300) mg
24–160
Y
Fixed
RR
0.67
0.42, 1.07
0.09
0
0.69
⨁⨁⨁◯
Moderate
Network meta-analysis
OR
1.02
0.84, 1.23
NR
22.8
NR
5
Azhari et al. [73]
NR
NR
y
NR
RR
1.21
1.01–1.45
0.04
32%
NR
⨁⨁◯◯
Low
1.08
0.73–1.59
0.70
15%
6
Azhari et al. [74]
NR
NR
Y
Fixed
RR
1.33
1.19–1.48
< 0.00001
NR
NR
⨁⨁◯◯
Low
7
Azharuddin et al. [67]
NR
30–104
UN
Fixed
OR
1.45
0.82–2.57
0.21
0%
0.86
⨁⨁⨁◯
Moderate
8
Azharuddin et al. [31]
Dapagliflozin (2.5, 5, 10), canagliflozin (100), Empagliflozin (5, 10, 25) mg
24-51w (n = 14),
52-160w (n = 26)
Y
Fixed
OR
Vs. Placebo canagliflozin (0.57)
dapagliflozin (0.58)
empagliflozin (0.78)
vs. active control
Overall (1.01)
canagliflozin (2.6)
dapagliflozin (2.6)
empagliflozin (3.7)
0.12–1.90
0.13–2.00
0.23–2.80
0.83–1.23
0.69–16.00
0.52–22.00
1.0–27.00
0.91
27
0.01
⨁⨁⨁⨁
High
9
Bai et al. [32]
NR
52–202
Y
UN
HR
1.07
0.98–1.17
0.152
0%
0.899
⨁⨁⨁⨁
High
10
Chai et al. [34]
NR
24–54
Y
Random
OR
DPP-4i vs. Insulin: 0.86
vs. Met: 1.41
vs. SU: 0.77
vs. TZD: 0.82
vs. AGI: 4.92
vs. Placebo:1.04
GLP-1RAs vs. Insulin: 1.05
vs. Met: 1.72
vs. SU: 0.94
vs. TZD: 1.00
vs. AGI: 5.99
vs. Placebo:1.27
SGLT-2i vs. Insulin:0.88
vs. Met: 1.44
vs. SU: 0.79
vs. TZD: 0.83
vs. AGI: 5.01
vs. Placebo:1.06
0.39–1.90
0.48–4.19
0.50–1.20
0.27–2.44
0.23–103.83
0.84–1.29
0.54–2.04
0.55–5.38
0.55–1.62
0.32–3.10
0.28–130.37
0.88–1.83
0.39–1.97
0.48–4.30
0.48–1.31
0.27–2.57
0.23–107.48
0.81–1.39
NR
NR
NR
⨁⨁◯◯
Low
11
Cao et al. [33]
Empagliflozin (10, 25), Canagliflozin, Sotagliflozin (200, 400), Dapagliflozin (10) mg
24–126
Y
Random
RR
0.78
0.42–1.46
0.44
NR
NR
⨁⨁⨁◯
Moderate
12
Chen et al. [65]
10 mg/d
Max. follow-up 4.2 years
Y
Fixed
OR
1.06
0.94–1.20
0.32
0
0.58
⨁⨁⨁◯
Moderate
13
Chen et al. [102]
NR
52
Y
Fixed
OR
1.01
0.90–1.12
0.92
0%
1.00
⨁⨁⨁◯
Moderate
14
Cheng et al. [65]
Dapagliflozin (2.5, 5, 10), Empagliflozin (10, 25), Canagliflozin (100, 300)
Dieser Beitrag wurde original veröffentlicht auf: link zum Beitrag
